School of Biotechnology, Southern Medical University, Guangzhou, China.
Hepatology. 2011 Jun;53(6):1932-42. doi: 10.1002/hep.24291. Epub 2011 May 2.
The activation of oncogenes and the inactivation of tumor suppressor genes by mutations or chronic hepatitis virus infections play key roles in the pathogenesis of hepatocellular carcinoma (HCC). Here we report that RN181, a really interesting new gene finger domain-containing protein, was down-regulated in highly malignant cell lines and in tumor cells of 139 HCC clinical samples in comparison with adjacent normal liver tissues. The expression of RN181 was strongly associated with the pathological grade of HCC. Alterations of the expression of RN181 by retrovirus-transduced up-regulation and short hairpin RNA-mediated down-regulation demonstrated the function of RN181 as a tumor suppressor because it decreased the proliferation and colony formation of HCC cells in vitro and inhibited tumor growth in vivo by suppressing cell proliferation and enhancing cell apoptosis in xenografted tumors. Proteomic analyses showed that RN181 regulates the expression of many proteins that are important in many cellular processes. Statistical analyses identified 33 proteins with consistent changes (≥2-fold) in RN181-transformed cells. Ten of these proteins were up-regulated by RN181, and 23 were down-regulated. Representative proteins were validated by western blotting. Interaction network investigations revealed that 20 RN181-regulated proteins could integrate several key biological processes such as survival, metabolism, and mitogen-activated protein kinase (MAPK) pathways. Remarkably, 11 of the 33 proteins are associated with MAPK signaling in one or more ways. RN181 suppressed the tyrosine phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in cell lines and in tumor cells of xenografts and HCC clinical samples, and removing the suppression increased tumor growth.
We have shown that RN181 suppresses the tumorigenesis of HCC through the inhibition of ERK/MAPK signaling in the liver. Our results provide new insights into the pathogenesis of HCC and may help with the development of novel therapeutic strategies.
癌基因的激活和肿瘤抑制基因的失活是导致肝细胞癌(HCC)发病的关键因素。我们在此报告,RN181,一个真正有趣的新基因指状结构域蛋白,在高度恶性细胞系和 139 例 HCC 临床样本的肿瘤细胞中下调,与相邻正常肝组织相比。RN181 的表达与 HCC 的病理分级强烈相关。逆转录病毒转导上调和短发夹 RNA 介导的下调改变 RN181 的表达,证明 RN181 作为肿瘤抑制因子的功能,因为它降低了 HCC 细胞在体外的增殖和集落形成,并通过抑制细胞增殖和增强细胞凋亡来抑制体内肿瘤生长异种移植瘤。蛋白质组学分析表明,RN181 调节许多在许多细胞过程中重要的蛋白质的表达。统计分析确定了 33 个在 RN181 转化细胞中一致变化(≥2 倍)的蛋白质。其中 10 个蛋白被 RN181 上调,23 个蛋白被下调。代表性蛋白通过 western blot 验证。相互作用网络研究表明,20 个 RN181 调控的蛋白可以整合几个关键的生物学过程,如存活、代谢和丝裂原活化蛋白激酶(MAPK)途径。值得注意的是,33 个蛋白质中有 11 个与 MAPK 信号通路在一种或多种方式有关。RN181 抑制细胞系和异种移植瘤和 HCC 临床样本肿瘤细胞中细胞外信号调节激酶 1/2(ERK1/2)的酪氨酸磷酸化,去除抑制作用增加肿瘤生长。
我们已经表明,RN181 通过抑制 ERK/MAPK 信号通路在肝脏中抑制 HCC 的肿瘤发生。我们的结果为 HCC 的发病机制提供了新的见解,并可能有助于开发新的治疗策略。